WEILL CORNELL MEDICINE

CareTech Human has secured $500,000 in pre-seed funding to conduct clinical trials of its toilet bowl-mounted device that passively monitors urological health parameters using infrared sensing and AI technology.

Biostate AI and Weill Cornell Medicine have formed a strategic collaboration to develop AI models for personalized leukemia care, initially focusing on acute myeloid leukemia (AML) using RNA sequencing technology.

A Phase I clinical trial by Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center shows that direct delivery of 124I-Omburtamab to treat diffuse intrinsic pontine glioma (DIPG) is safe and feasible.

Weill Cornell Medicine researchers demonstrated that deleting the SATB2 gene in colon cells reprograms them to function like small intestine cells, potentially offering a new treatment approach for short bowel syndrome.

Baird Medical has received regulatory approval from Indonesia's Ministry of Health for its Great Wall Microwave Therapeutic Instrument and Disposable Microwave Ablation Needle, marking a significant expansion into Southeast Asia.

The ProstACT GLOBAL trial is evaluating 177Lu-TLX591 plus standard of care (SOC) versus SOC alone in metastatic castration-resistant prostate cancer (mCRPC) patients.

A new study reveals that the HepB-CpG vaccine (Heplisav-B) provides significantly better protection against hepatitis B for people with HIV compared to the older HepB-alum vaccine.

EZH2 inhibitors, like tazemetostat and valemetostat, enhance T-cell-based immunotherapies against B-cell non-Hodgkin lymphomas in preclinical models.

Researchers identified that the enzyme EZH2 shifts its function in the absence of PKCλ/ι, promoting tumor growth in aggressive prostate cancer.

Researchers have discovered that the EZH2 enzyme promotes aggressive tumor growth in prostate cancers resistant to treatment.